Published in Hautarzt on May 01, 1978
Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study. Leukemia (2011) 4.47
Response to thalidomide in progressive multiple myeloma is not mediated by inhibition of angiogenic cytokine secretion. Br J Haematol (2001) 1.68
Quality of life and rehabilitation in social and professional life after autologous stem cell transplantation. Ann Oncol (2002) 1.67
High plasma basic fibroblast growth factor concentration is associated with response to thalidomide in progressive multiple myeloma. Clin Cancer Res (2001) 1.51
Efficacy and safety of bortezomib in patients with renal impairment: results from the APEX phase 3 study. Leukemia (2008) 1.46
Combining fluorescent in situ hybridization data with ISS staging improves risk assessment in myeloma: an International Myeloma Working Group collaborative project. Leukemia (2012) 1.43
Peripherally inserted central venous catheters for autologous blood progenitor cell transplantation in patients with haematological malignancies. Support Care Cancer (2003) 1.39
Acne fulminans: investigation of acute febrile ulcerative acne. Arch Dermatol (1977) 1.39
A gene expression signature for high-risk multiple myeloma. Leukemia (2012) 1.36
Prognostic factors for donor lymphocyte infusions following non-myeloablative allogeneic stem cell transplantation in multiple myeloma. Bone Marrow Transplant (2006) 1.29
Thalidomide in newly diagnosed multiple myeloma: influence of thalidomide treatment on peripheral blood stem cell collection yield. Leukemia (2007) 1.28
Long-term outcome of nonmyeloablative allogeneic transplantation in patients with high-risk multiple myeloma. Bone Marrow Transplant (2005) 1.27
Heparan sulphate proteoglycans are essential for the myeloma cell growth activity of EGF-family ligands in multiple myeloma. Oncogene (2006) 1.21
Atacicept in relapsed/refractory multiple myeloma or active Waldenström's macroglobulinemia: a phase I study. Br J Cancer (2009) 1.17
Patient characteristics associated with successful mobilizing and autografting of peripheral blood progenitor cells in malignant lymphoma. Blood (1994) 1.13
Bone morphogenic protein 6: a member of a novel class of prognostic factors expressed by normal and malignant plasma cells inhibiting proliferation and angiogenesis. Oncogene (2009) 1.10
Diffuse and banded melanin pigmentation in nails. Arch Dermatol (1972) 1.09
Alterations of the cyclin D1/pRb/p16(INK4A) pathway in multiple myeloma. Leukemia (2002) 1.09
Clonotypic CD20+ and CD19+ B cells in peripheral blood of patients with multiple myeloma post high-dose therapy and peripheral blood stem cell transplantation. Br J Haematol (1999) 1.06
Autologous stem cell transplantation for elderly patients with newly diagnosed multiple myeloma in the era of novel agents. Ann Oncol (2014) 1.05
Reactions to ionizing radiation. J Am Acad Dermatol (1980) 1.04
Angiogenesis in hematologic malignancies. Crit Rev Oncol Hematol (2003) 1.04
Dermatitis associated with an implanted cardiac pacemaker. Arch Dermatol (1970) 1.03
Insulin is a potent myeloma cell growth factor through insulin/IGF-1 hybrid receptor activation. Leukemia (2010) 1.03
High-dose chemotherapy with autologous peripheral blood stem cell transplantation for bone and soft-tissue sarcomas. Bone Marrow Transplant (2004) 1.00
Bone marrow microcirculation analysis in multiple myeloma by contrast-enhanced dynamic magnetic resonance imaging. Int J Cancer (2001) 0.99
High incidence of trisomies 1q, 9q, and 11q in multiple myeloma: results from a comprehensive molecular cytogenetic analysis. Leukemia (2003) 0.99
Bisphosphonates in multiple myeloma. Cochrane Database Syst Rev (2002) 0.97
[Trichostasis spinulosa. A frequent follicular age-dependent change of the facial skin]. Hautarzt (1975) 0.93
Radiotherapy of skin cancer: modern indications and techniques. Cutis (1976) 0.92
Chromosomal aberrations in 130 patients with multiple myeloma studied by interphase FISH: diagnostic and prognostic relevance. Cancer Genet Cytogenet (2006) 0.92
Analysis of p73 and p53 gene deletions in multiple myeloma. Leukemia (1999) 0.90
Alpha-interferon maintenance treatment is associated with improved survival after high-dose treatment and autologous stem cell transplantation in patients with multiple myeloma: a retrospective registry study from the European Group for Blood and Marrow Transplantation (EBMT). Bone Marrow Transplant (2001) 0.90
Preoperative elevation of serum C--reactive protein is predictive for prognosis in myeloma bone disease after surgery. Br J Cancer (2006) 0.88
A quantitative PCR assay for the detection of low amounts of malignant cells in multiple myeloma. Ann Oncol (1997) 0.88
Prevention of venous thromboembolism with low molecular-weight heparin in patients with multiple myeloma treated with thalidomide and chemotherapy. Leukemia (2004) 0.87
Mobilization of peripheral blood stem cells for autologous transplant in non-Hodgkin's lymphoma and multiple myeloma patients by plerixafor and G-CSF and detection of tumor cell mobilization by PCR in multiple myeloma patients. Bone Marrow Transplant (2009) 0.86
Lack of CD56 expression on myeloma cells is not a marker for poor prognosis in patients treated by high-dose chemotherapy and is associated with translocation t(11;14). Bone Marrow Transplant (2007) 0.86
Influence of index of individuality on false positives in repeated sampling from healthy individuals. Clin Chem Lab Med (2001) 0.85
Bladder necrosis caused by use of THAM in a newborn infant. J Urol (1974) 0.84
The index of individuality is often a misinterpreted quantity characteristic. Clin Chem Lab Med (1999) 0.84
Inflammatory autoimmune neuropathy, presumably induced by bortezomib, in a patient suffering from multiple myeloma. Int J Hematol (2011) 0.84
Myeloablative therapy with blood stem cell transplantation is effective in mantle cell lymphoma. Leukemia (1996) 0.84
Angiogenesis in hematologic malignancies. Ann Hematol (2001) 0.83
Clinical significance of cyclooxygenase-2 (COX-2) in multiple myeloma. Swiss Med Wkly (2006) 0.83
Analysis of circulating tumor cells in patients with multiple myeloma during the course of high-dose therapy with peripheral blood stem cell transplantation. Bone Marrow Transplant (1999) 0.83
Exfoliative cytology of human horny layer. Methods of cell removal and microscopic techniques. Arch Dermatol (1967) 0.82
Salvage therapy for multiple myeloma with thalidomide and CED chemotherapy. Blood (2001) 0.81
Increased sebum secretion following selenium sulfide shampoos. Acta Derm Venereol (1968) 0.81
No evidence for involvement of alleles of the 825-C/T polymorphism of the G-protein subunit beta 3 in body weight regulation. Exp Clin Endocrinol Diabetes (2001) 0.81
Surface area measurements of psoriatic corneocytes: effects of intralesional steriod therapy. J Invest Dermatol (1979) 0.81
No evidence for involvement of the promoter polymorphism -866 G/A of the UCP2 gene in childhood-onset obesity in humans. Exp Clin Endocrinol Diabetes (2003) 0.81
Dendritic cells generated from the blood of patients with multiple myeloma are phenotypically and functionally identical to those similarly produced from healthy donors. Br J Haematol (1997) 0.81
Desquamation of the human horny layer. Arch Dermatol (1967) 0.81
Gene expression-based prediction of myeloma cell sensitivity to histone deacetylase inhibitors. Br J Cancer (2013) 0.80
Malignant lymphoma, reticulum cell type. Ultrastructural and cytological demonstration of Lutzner cells. Arch Dermatol (1971) 0.80
Successful autografting following myeloablative conditioning therapy with blood stem cells mobilized by chemotherapy plus rhG-CSF. Exp Hematol (1993) 0.80
Altered self-reactive antibody repertoires are a general feature of patients with myelodysplastic syndrome. J Autoimmun (2001) 0.80
[Effects of a programme for structured outpatient follow-up care after inpatient rehabilitation of obese children and adolescents--a multicentre, randomized study]. Rehabilitation (Stuttg) (2006) 0.80
Molecular monitoring of the tumor load predicts progressive disease in patients with multiple myeloma after high-dose therapy with autologous peripheral blood stem cell transplantation. Bone Marrow Transplant (2001) 0.79
Efficient mobilization of peripheral blood stem cells following CAD chemotherapy and a single dose of pegylated G-CSF in patients with multiple myeloma. Bone Marrow Transplant (2007) 0.79
The dose of granulocyte colony-stimulating factor administered following cytotoxic chemotherapy is not related to the rebound level of circulating CD34+ haemopoietic progenitor cells during marrow recovery. Br J Haematol (1998) 0.79
Anti-CD20 antibody as consolidation therapy in a patient with primary plasma cell leukemia after high-dose therapy and autologous stem cell transplantation. Ann Hematol (2001) 0.79
Dermatologic radiotherapy and thyroid cancer. Dose measurements and risk quantification. Arch Dermatol (1983) 0.79
Long-term survival in a patient with AL amyloidosis after cardiac transplantation followed by autologous stem cell transplantation. Clin Res Cardiol (2006) 0.78
Tandem high-dose therapy with ifosfamide, epirubicin, carboplatin and peripheral blood stem cell support is an effective adjuvant treatment for high-risk primary breast cancer. Eur J Cancer (1997) 0.78
Bisphosphonates in multiple myeloma. Cochrane Database Syst Rev (2001) 0.78
Piperacillin/tazobactam vs ceftazidime in the treatment of neutropenic fever in patients with acute leukemia or following autologous peripheral blood stem cell transplantation: a prospective randomized trial. Bone Marrow Transplant (2006) 0.78
Central venous catheter-related complications. Antibiot Chemother (1971) (2000) 0.78
Continuous infusion of ceftazidime for patients with breast cancer and multiple myeloma receiving high-dose chemotherapy and peripheral blood stem cell transplantation. Bone Marrow Transplant (2002) 0.78
Dermatologic radiotherapy. The risk-benefit ratio. Arch Dermatol (1986) 0.78
Office radiotherapy of cutaneous carcinomas. II. Indications in specific anatomic regions. J Dermatol Surg Oncol (1983) 0.78
CD19+ and CD20+ B cells from the peripheral blood of patients with multiple myeloma are not infected with human herpesvirus 8. Leukemia (2000) 0.78
[Correlation of MRI and histopathology of bone marrow in patients with multiple myeloma]. Rofo (2005) 0.77
Blood-derived autografts collected during granulocyte colony-stimulating factor-enhanced recovery are enriched with early Thy-1+ hematopoietic progenitor cells. Blood (1995) 0.77
Tandem and triple high-dose chemotherapy with autologous stem cell rescue in metastatic breast cancer. J Cancer Res Clin Oncol (1998) 0.77
Ceftriaxone for the treatment of febrile episodes in nonneutropenic patients with hematooncological disease or HIV infection: comparison of outpatient and inpatient care. Chemotherapy (2001) 0.77
Transient complete remission of metastasized Merkel cell carcinoma by high-dose polychemotherapy and autologous peripheral blood stem cell transplantation. Br J Dermatol (2000) 0.77
Continuous complete remission in adult patients with acute lymphocytic leukaemia at a median observation of 12 years after autologous bone marrow transplantation. Br J Haematol (2001) 0.77
A rationale for positive selection of peripheral blood stem cells in multiple myeloma: highly purified CD34+ cell fractions of leukapheresis products do not contain malignant cells. Leukemia (1997) 0.77
Long-term survival after surgical intervention for bone disease in multiple myeloma. Ann Oncol (2005) 0.77
Evaluation of tumour metabolism and multidrug resistance in patients with treated malignant lymphomas. Eur J Nucl Med (1995) 0.77
Contact radiotherapy of cutaneous hemangiomas: therapeutic effects and radiation sequelae in 818 patients. Arch Dermatol Res (1975) 0.77
[Dermatologic roentgen therapy and radiocarcinogenesis]. Hautarzt (1982) 0.77
Large-bore central venous catheters for the collection of peripheral blood stem cells. J Clin Apher (1995) 0.77
Successful autologous peripheral blood stem cell transplantation in a Jehovah's Witness with multiple myeloma: review of literature and recommendations for high-dose chemotherapy without support of allogeneic blood products. Int J Hematol (2008) 0.77
High-dose therapy with peripheral blood progenitor cell transplantation in low-grade non-Hodgkin's lymphoma. Bone Marrow Transplant (1996) 0.77
Evaluation of the kinetics of the bone marrow tumor load in the course of sequential high-dose therapy assessed by quantitative PCR as a predictive parameter in patients with multiple myeloma. Bone Marrow Transplant (2000) 0.76
Successful collection and transplantation of peripheral blood stem cells in cancer patients using large-volume leukaphereses. J Clin Apher (1996) 0.76
Stage III and oestrogen receptor negativity are associated with poor prognosis after adjuvant high-dose therapy in high-risk breast cancer. Br J Cancer (1999) 0.76
Efficacy of continuous infusion of ceftazidime for patients with neutropenic fever after high-dose chemotherapy and peripheral blood stem cell transplantation. Int J Antimicrob Agents (2000) 0.76
Recombinant human granulocyte and granulocyte-macrophage colony-stimulating factor (G-CSF and GM-CSF) administered following cytotoxic chemotherapy have a similar ability to mobilize peripheral blood stem cells. Bone Marrow Transplant (1998) 0.76
Autografting with peripheral blood stem cells mobilized by sequential interleukin-3/granulocyte-macrophage colony-stimulating factor following high-dose chemotherapy in non-Hodgkin's lymphoma. Bone Marrow Transplant (1993) 0.76
Radiotherapy of benign dermatoses: indications, practice, and results. J Dermatol Surg Oncol (1978) 0.76
Combination therapy of Thalidomide and Peginterferon in patients with progressive multiple myeloma. Ann Oncol (2004) 0.76
Decreased numbers of circulating B cells in myeloma patients with reduction after conventional chemotherapy. Am J Hematol (1998) 0.76
Detection of treated liver metastases using fluorine-18-fluordeoxyglucose (FDG) and positron emission tomography (PET). Anticancer Res (2000) 0.76